NAS:DNLI (USA) Also Trade In: Germany
Denali Therapeutics Inc $ 15.17 0.77 (5.35%)
Warning! GuruFocus has detected 1 Severe warning sign with DNLI. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for DNLI (Denali Therapeutics) from 2017 to Oct 22 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Denali Therapeutics stock (DNLI) PE ratio as of Oct 22 2019 is 0. More Details
Denali Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Denali Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Industry Biotechnology » Biotechnology NAICS : 325414 NAICS : 2836
Compare LSE:GNS XMCE:ALM ROCO:4147 NAS:PTLA NYSE:XON SZSE:300294 XKRX:006280 NAS:CORT SZSE:002287 NAS:AKCA SZSE:002653 NAS:SGMO NAS:ESPR NAS:RXDX NAS:MYOK NAS:XLRN NAS:EDIT XKRX:095700 NAS:SPPI NYSE:CBM
Address 151 Oyster Point Boulevard, 2nd Floor, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others.